Emergent BioSolutions (EBS) Net Cash Flow (2010 - 2026)

Emergent BioSolutions' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$47.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 199.37% year-over-year to -$47.6 million; the TTM figure through Mar 2026 stood at $7.9 million (down 89.4% YoY), while the FY2025 annual figure was $103.4 million, up 1795.08% from the prior year.
• Net Cash Flow was -$47.6 million for Q1 2026 at Emergent BioSolutions, down from -$40.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $400.5 million in Q4 2022 to a low of -$343.6 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$24.4 million across 5 years, with a median of -$32.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow sank 338.27% in 2023, then soared 4594.74% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $400.5 million in 2022, then slumped by 93.66% to $25.4 million in 2023, then tumbled by 300.0% to -$50.8 million in 2024, then increased by 21.06% to -$40.1 million in 2025, then fell by 18.7% to -$47.6 million in 2026.
• The last three Net Cash Flow figures came in at -$47.6 million (Q1 2026), -$40.1 million (Q4 2025), and -$21.6 million (Q3 2025), per Business Quant data.